Skip to main content

Advertisement

SpringerLink
Log in

Current Review on High-Risk Multiple Myeloma

  • Multiple Myeloma (P Kapoor, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

New risk stratification systems and treatment strategies have been introduced in recent years. We aim to provide an overview of these recent changes and summarise these data in a concise article that would be useful for clinicians.

Recent Findings

Apart from clinical stage, disease genetics are now recognised as important prognostic risk factors, and various new cytogenetic changes with negative prognostic impact have been identified. New technologies such as minimal residual disease detection are also playing an important role in prognostic assessment. Recent introduction of combination therapy with proteasome inhibitors and immunomodulatory drugs is showing promising results in high-risk patients and may partially abrogate the negative impact associated with some of the adverse risk factors.

Summary

Recent advance has improved our understanding of high-risk multiple myeloma, and new therapeutic agents are now coming through the pipeline for this patient group with once dismal outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26(2):349–55.

    Article  CAS  PubMed  Google Scholar 

  2. •• Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(26):2863–9. This study highlights the importance of chromosomal abnormalities and LDH in risk stratification, and provides an update on the prognosis for patients in the era of novel agents.

  3. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of Multiple Myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-62.

  4. •• Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068–74. This is the first prospective study that evaluates the role of comprehensive geriatric assessment when managing elderly patients with multiple myeloma. It highlights the fact that frailty itself can be a risk factor for reduced treatment tolerance and inferior survival outcomes.

  5. Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761–7.

    Article  PubMed  PubMed Central  Google Scholar 

  6. • Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360–4. This study has one of the largest series of patients with extramedullary relapse, and it is one of the first papers to demonstrate the difference in prognosis between various extramedullary relapse.

  7. Usmani SZ, Rodriguez-Otero P, Bhutani M, Mateos MV, Miguel JS. Defining and treating high-risk multiple myeloma. Leukemia. 2015;29(11):2119–25.

    Article  CAS  PubMed  Google Scholar 

  8. • An G, Li Z, Tai YT, Acharya C, Li Q, Qin X, et al. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(9):2148–56. This paper and the one published by Merz et al both demonstrate the importance of clonal size when interpreting the prognostic significance of del(17p).

  9. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489–95.

    Article  CAS  PubMed  Google Scholar 

  10. • Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, et al. Baseline characteristics, chromosomal alterations and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. Am J Hematol. 2016. This paper and the one published by An et al both demonstrate the importance of clonal size when interpreting the prognostic significance of del(17p).

  11. Moreau P, Attal M, Garban F, Hulin C, Facon T, Marit G, et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia. 2007;21(9):2020–4.

    Article  CAS  PubMed  Google Scholar 

  12. Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9–19.

    Article  CAS  PubMed  Google Scholar 

  13. • Kaufman GP, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, et al. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia. 2016;30(3):633–9. This study demonstrates that t(4;14) may not be as high-risk as previously thought when treated with proteasome inhibitor based treatment. It also finds that patients with t(11;14) do not seem to response well with bortezomib as much as other subgroups.

  14. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360–76.

    Article  PubMed  Google Scholar 

  15. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569–75.

    Article  CAS  PubMed  Google Scholar 

  16. Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia. 2014;28(2):398–403.

    Article  CAS  PubMed  Google Scholar 

  17. Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(16):1949–52.

    Article  Google Scholar 

  18. Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 2014;28(3):675–9.

    Article  CAS  PubMed  Google Scholar 

  19. Kim M, Lee SH, Kim J, Lee SE, Kim YJ, Min CK. Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. Genes, Chromosomes Cancer. 2015;54(1):20–7.

    Article  PubMed  Google Scholar 

  20. Ouyang J, Gou X, Ma Y, Huang Q, Jiang T. Prognostic value of 1p deletion for multiple myeloma: a meta-analysis. Int J Lab Hematol. 2014;36(5):555–65.

    Article  CAS  PubMed  Google Scholar 

  21. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276–84.

    Article  CAS  PubMed  Google Scholar 

  22. Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011;118(16):4359–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(29):4798–805.

    Article  CAS  Google Scholar 

  24. Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010;16(6):1856–64.

    Article  CAS  Google Scholar 

  25. Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26(11):2406–13.

    Article  CAS  PubMed  Google Scholar 

  26. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(33):3911–20.

    Article  CAS  Google Scholar 

  27. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(24):2946–55.

    Article  CAS  Google Scholar 

  28. Jimenez-Zepeda VH, Duggan P, Neri P, Rashid-Kolvear F, Tay J, Bahlis NJ. Revised International Staging System applied to real world multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2016;16(9):511–8.

    Article  PubMed  Google Scholar 

  29. • Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, et al. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(20):2173–80. This is one of the earlier studies that incorporate clinical stage, LDH and chromosomal abnormalities in risk stratification. Their results help support the adoption of the later published revised International Staging System.

  30. Fernandez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27(4):780–91.

    Article  CAS  PubMed  Google Scholar 

  31. Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124(6):907–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. • Gonsalves WI, Rajkumar SV, Gupta V, Morice WG, Timm MM, Singh PP, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia. 2014;28(10):2060–5. This is one of the first articles that evaluate the role of peripheral blood flow cytometry for the purpose of risk stratification in patients with multiple myeloma.

  33. Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008;111(8):4039–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Rios-Tamayo R, Sainz J, Martinez-Lopez J, Puerta JM, Chang DY, Rodriguez T, et al. Early mortality in multiple myeloma: the time-dependent impact of comorbidity: a population-based study in 621 real-life patients. Am J Hematol. 2016;91(7):700–4.

    Article  PubMed  Google Scholar 

  35. San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008;22(4):842–9.

    Article  CAS  PubMed  Google Scholar 

  36. Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. 2014;99(1):148–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. • Binder M, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, et al. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. Am J Hematol. 2015;90(10):888–91. Their results show that renal impairment at the time of presentation is no longer a significant risk factor.

  38. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(15):3412–20.

    Article  Google Scholar 

  39. • Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013;27(3):711–7. This is one of the earlier studies that incorporate clinical stage and chromosomal abnormalities in risk stratification. Their results help support the adoption of the later published revised International Staging System.

  40. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101(4):1520–9.

    Article  CAS  PubMed  Google Scholar 

  41. Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood cancer journal. 2015;5:e365.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2(3):175–87.

    Article  CAS  PubMed  Google Scholar 

  43. Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood cancer journal. 2012;2, e89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Karlin L, Soulier J, Chandesris O, Choquet S, Belhadj K, Macro M, et al. Clinical and biological features of t(4;14) multiple myeloma: a prospective study. Leuk Lymphoma. 2011;52(2):238–46.

    Article  CAS  PubMed  Google Scholar 

  45. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005–01 phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(30):4621–9.

    Article  CAS  Google Scholar 

  46. Chan H, Phillips M, Farooki S, Rodriguez G, Masih-Khan E, Chen C, et al. Single centre experience in treating newly diagnosed t(4;14) multiple myeloma with and without planned front-line autologous stem cell transplant [abstract]. Blood (ASH Annual Meeting Abstracts). 2016;128(22):3457.

    Google Scholar 

  47. McKenna RW, Kyle RA, Kuehi WM, Grogan TM, Harris NL RWC. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, editors. World Health Organization classification of tumours pathology and genetics of tumours of the haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 240–1.

    Google Scholar 

  48. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119(9):2100–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B, et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011;117(6):2009–11.

  50. Sergentanis TN, Kastritis E, Terpos E, Dimopoulos MA, Psaltopoulou T. Cytogenetics and survival of multiple myeloma: isolated and combined effects. Clinical lymphoma, myeloma & leukemia. 2016

  51. Hebraud B, Magrangeas F, Cleynen A, Lauwers-Cances V, Chretien ML, Hulin C, et al. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood. 2015;125(13):2095–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–54.

    Article  CAS  PubMed  Google Scholar 

  53. Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia. 2009;23(6):1152–7.

    Article  CAS  PubMed  Google Scholar 

  54. Dunavin NC, Wei L, Elder P, Phillips GS, Benson Jr DM, Hofmeister CC, et al. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. Leuk Lymphoma. 2013;54(8):1658–64.

    Article  CAS  PubMed  Google Scholar 

  55. Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120(8):1589–96.

    Article  CAS  PubMed  Google Scholar 

  56. Haessler J, Shaughnessy Jr JD, Zhan F, Crowley J, Epstein J, van Rhee F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(23):7073–9.

    Article  CAS  Google Scholar 

  57. Landgren O, Devlin S, Boulad M, Mailankody S. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant. 2016.

  58. Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125(12):1932–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016;127(25):3165–74.

    Article  CAS  PubMed  Google Scholar 

  61. Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687–91.

    Article  CAS  PubMed  Google Scholar 

  62. Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016

  63. Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta JJ, Cavo M, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(26):3279–87.

    Article  CAS  Google Scholar 

  64. Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant. 2015;50(2):204–8.

    Article  CAS  PubMed  Google Scholar 

  65. Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005–04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(20):2475–82.

    Article  CAS  Google Scholar 

  66. Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940–8.

    Article  CAS  PubMed  Google Scholar 

  67. Sonneveld P, Salwender H-J, Van Der Holt B, el Jarari L, Bertsch U, Blau IW, et al. Bortezomib induction and maintenance in patients with newly diagnosed multiple myeloma: long-term follow-up of the HOVON-65/GMMG-HD4 Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2015;126(23):27.

    Google Scholar 

  68. Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(30):4630–4.

    Article  CAS  Google Scholar 

  69. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(28):4459–65.

    Article  CAS  Google Scholar 

  70. Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114(3):522–5.

    Article  CAS  PubMed  Google Scholar 

  71. Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009;113(18):4137–43.

    Article  CAS  PubMed  Google Scholar 

  72. Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia. 2010;24(3):623–8.

    Article  CAS  PubMed  Google Scholar 

  73. • Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014;28(3):690–3. In patients with high-risk disease, the option of prolonged RVD consolidation followed by single agent lenalidomide maintenance can be a viable option following autologous stem cell transplant with promising long-term outcomes.

  74. Attal M, Lauwers-Cances V, Hulin C, Facon T, Caillot D, Escoffre M, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial) [abstract]. Blood (ASH Annual Meeting Abstracts). 2015;126(23):391.

    Google Scholar 

  75. Durie B, Hoering A, Rajkumar SV, Abidi MH, Epstein J, Kahanic SP, et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777 [abstract]. Blood (ASH Annual Meeting Abstracts). 2015;126(23):25.

    Google Scholar 

  76. Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014;15(13):1503–12.

    Article  CAS  PubMed  Google Scholar 

  78. •• Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016;128(9):1174–80. The ASPIRE study is the first phase 3 trial evaluating the role of carfilzomib on a lenalidomidedexamethasone backbone. The result of the study demonstrates a significant improvement in longterm outcomes not previously seen in other prior studies. This latest paper also shows that the improvement in outcomes also extend to those with high-risk myeloma.

  79. •• Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–34. This is the first phase 3 study on the combination of ixazomib, lenalidomide and dexamethasone. Apart from the improvement in outcomes compared with lenalidomide and dexamethasone alone, it also finds the ixazomib combination to be very tolerable with good treatment adherence, making it an attractive all-oral option for patients with relapsed disease.

  80. Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015;100(10):1327–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126(20):2284–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617–29.

    Article  CAS  PubMed  Google Scholar 

  83. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905.

    Article  PubMed  Google Scholar 

  84. Cavo M, Palumbo A, Zweegman S, Dimopoulos MA, Hajek R, Pantani L, et al. Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial) [abstract]. J Clin Oncol (ASCO Annual Meeting). 2016;34

  85. Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101(2):100–6.

    Article  CAS  PubMed  Google Scholar 

  86. Mai EK, Benner A, Bertsch U, Brossart P, Hanel A, Kunzmann V, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol. 2016;173(5):731–41.

    Article  CAS  PubMed  Google Scholar 

  87. • Cavo M, Salwender H, Rosiñol L, Moreau P, Petrucci MT, Blau IW, et al. Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from phase European III studies [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21):767. This study finds that patients who failed to achieve complete response after first autologous stem cell transplant and those with high-risk cytogenetic features benefit the most from tandem autologous stem cell transplantation.

  88. Parmar G, Masih-khan E, Atenafu EG, Reece DE, Trudel S, Tiedemann RE, et al. Outcome of 17p deleted multiple myeloma (MM) in the era of novel agents and tandem transplantation: a single centre experience [abstract]. Blood (ASH Annual Meeting Abstracts). 2014;124(21):4756.

    Google Scholar 

  89. • Cavo M, Petrucci MT, Di Raimondo F, Zamagni E, Gamberi B, Crippa C, et al. Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02/HO95 MM Trial) [abstract]. Blood (ASH Annual Meeting Abstracts). 2016;128(22):991. The preliminary results from this study provides prospective evidence in support of the use of tandem autologous stem cell transplant in patients with high-risk multiple myeloma.

  90. • Stadtmauer EA, Pasquini MC, Blackwell B, Knust K, Bashey A, Devine SM, et al. Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem autoHCT with Len maintenance (TAM) and autoHCT with Len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 - StaMINA Trial) [abstract]. Blood (ASH Annual Meeting Abstracts). 2016;128(22):LBA-1-LBA. The preliminary results from this study shows no benefit of tandem over single autologous stem cell transplant even in patients with high-risk multiple myeloma.

  91. Kroger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013;19(3):398–404.

    Article  Google Scholar 

  92. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea 3rd E, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12(13):1195–203.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Dhakal B, Vesole DH, Hari PN. Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant. 2016;51(4):492–500.

    Article  CAS  PubMed  Google Scholar 

  94. Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 2013;121(25):5055–63.

    Article  CAS  PubMed  Google Scholar 

  95. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–91.

    Article  CAS  PubMed  Google Scholar 

  96. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. •• Attal M, Palumbo A, Holstein SA, Lauwers-Cances V, Petrucci MT, Richardson PG, et al. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): a meta-analysis (MA) of overall survival (OS). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;(suppl; abstr 8001):34. This meta-analysis demonstrates improved overall survival with lenalidomide maintenance following autologous stem cell transplant. However, the preliminary data presented in this abstract shows no benefit in patients with high-risk cytogenetics.

  98. • Sivaraj D, Green MM, Li Z, Sung AD, Sarantopoulos S, Kang Y, et al. Outcomes of maintenance therapy with bortezomib post-autologous stem cell transplantation for patients with multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2016. This retrospective analysis shows that maintenance bortezomib given every 2 weeks either alone or in combination with lenalidomide is feasible and may abrogate some of the adverse prognostic impact of high-risk cytogenetics.

  99. Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010–02 trial results. Blood. 2015;125(9):1411–7.

    Article  CAS  PubMed  Google Scholar 

  100. • Baz RC, Martin 3rd TG, Lin HY, Zhao X, Shain KH, Cho HJ, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016;127(21):2561–8. This study provides early evidence that pomalidomide-based triplet regimens is effective in patients with high-risk multiple myeloma.

  101. Lacy MQ, LaPlant BR, Laumann KM, Kumar S, Gertz MA, Hayman SR, et al. Pomalidomide, bortezomib and dexamethasone (PVD) for patients with relapsed lenalidomide refractory multiple myeloma (MM). Blood. 2014;124(21):304.

    Google Scholar 

  102. •• Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31. This study highlights the efficacy of elotuzumab when given in conjunction with lenalidomide and dexamethasone, despite only having modest effect as a single agent. This combination is also effective in patients with high-risk cytogenetics.

  103. •• Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–66. This is the first phase 3 study on this combination and it shows a significant improvement in PFS. With the HR of 0.39, this result is one of the best seen in patients treated in the relapsed setting.

  104. •• Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31. Apart from showing an improved outcome for the patients in the daratumumab arm, the result of the study also demonstrates a high percentage of MRD negativity with the addition of daratumumab to a lenalidomide-dexamethasone backbone.

Download references

Author information

Authors and Affiliations

  1. Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2M9, Canada

    Henry S. H. Chan, Christine I. Chen & Donna E. Reece

Authors
  1. Henry S. H. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine I. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donna E. Reece
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donna E. Reece.

Ethics declarations

Conflict of Interest

Henry SH. Chan declares no potential conflicts of interest. Christine I. Chen is an advisor and reports honorarium from Celgene, Agmen, and Janssen. Donna E. Reece is an advisor and reports honorarium from Celgene and Janssen and a grant from Janssen.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Multiple Myeloma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chan, H.S.H., Chen, C.I. & Reece, D.E. Current Review on High-Risk Multiple Myeloma. Curr Hematol Malig Rep 12, 96–108 (2017). https://doi.org/10.1007/s11899-017-0368-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-017-0368-z

Keywords

Search

Navigation